View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 18, 2022

Menarini unveils CoronaMeltVAR kit to detect Covid-19 and Omicron variant

CoronaMeltVAR releases a distinct signal following the detection of Omicron BA.1, BA.2, Alpha, Beta/Gamma or wild type/Delta.

Menarini Diagnostics has introduced its new CE-IVD real-time PCR kit, CoronaMeltVAR, for detecting SARS CoV-2 and identifying the Omicron variant.

The kit is designed to detect viral RNA from oropharyngeal, nasopharyngeal and saliva swabs and provides results in less than two hours.

Through the amplification of two targets, which are compatible with all variants as well as the wild type form, CoronaMeltVAR can identify positive samples with high sensitivity.

It also releases a distinct signal following the detection of the Omicron variant BA.1, BA.2, Alpha, Beta/Gamma or wild type/Delta.

The kit is based on RT-PCR amplification, with intercalating dye and melting curve analysis, for confirming the amplified product’s identity.

Menarini Silicon Biosystems chairman and CEO and A.Menarini Diagnostics general manager and global head Fabio Piazzalunga said: “We are extremely proud to have made this unique solution available so quickly. It is helping healthcare professionals in providing a specific, rapid and accurate solution for the diagnosis and identification of Covid-19 Omicron variant.”

A.Menarini Diagnostics forms part of the Menarini Pharmaceutical Group.

The kit provides all responses in a single run from each sample and eliminates the need for a second reflex test on positive samples.

According to the company, CoronaMeltVAR is compatible with most RNA extraction systems, as well as RT-PCR instruments that can perform melting curve analysis at moderate resolution.

In 2020, Menarini Silicon Biosystems reported data from a Phase III STIC CTC study that supported the reliability of using circulating tumour cell count to guide frontline therapy choice for estrogen receptor-positive (ER+), HER2-negative (HER2) metastatic breast cancer patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network